Azithromycin + Azithromycin and amoxicillin + Placebo
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Postpartum Sepsis
Conditions
Postpartum Sepsis, Postpartum Endometritis, Postpartum Fever
Trial Timeline
Jan 12, 2018 → Oct 1, 2020
NCT ID
NCT03248297About Azithromycin + Azithromycin and amoxicillin + Placebo
Azithromycin + Azithromycin and amoxicillin + Placebo is a approved stage product being developed by Merck for Postpartum Sepsis. The current trial status is completed. This product is registered under clinical trial identifier NCT03248297. Target conditions include Postpartum Sepsis, Postpartum Endometritis, Postpartum Fever.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03248297 | Approved | Completed |
Competing Products
20 competing products in Postpartum Sepsis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Misoprostol + Oxytocin | Cipla | Phase 3 | 77 |
| Quetiapine | AstraZeneca | Phase 2 | 52 |
| Eptacog alfa (NovoSeven) | Novo Nordisk | Approved | 84 |
| Eptacog alfa (activated) | Novo Nordisk | Pre-clinical | 22 |
| aripiprazole | Bristol Myers Squibb | Phase 3 | 76 |
| fibrinogen concentrate + Placebo | CSL | Phase 1/2 | 40 |
| SAGE-217 15/20 mg Oral Solution + Placebo + SAGE 217 30 mg Capsules | Biogen | Phase 3 | 74 |
| SAGE-217 + Placebo | Biogen | Phase 3 | 74 |
| Zuranolone | Biogen | Pre-clinical | 20 |
| Zuranolone | Biogen | Pre-clinical | 20 |
| LPCN 1154A + Placebo | Lipocine | Phase 3 | 69 |
| Goserelin 3.6 mg implant + Placebo | Brain Biotech | Pre-clinical | 15 |
| ZULRESSO (brexanolone) injection | Supernus Pharmaceuticals | Pre-clinical | 18 |
| Placebo + SAGE-547 90 μg/kg/h | Supernus Pharmaceuticals | Phase 3 | 72 |
| ZULRESSO® | Supernus Pharmaceuticals | Approved | 80 |
| SAGE-547 | Supernus Pharmaceuticals | Phase 2 | 47 |
| Placebo + SAGE-547 60 μg/kg/h + SAGE-547 90 μg/kg/h | Supernus Pharmaceuticals | Phase 3 | 72 |
| SAGE-547 + Placebo | Supernus Pharmaceuticals | Phase 2 | 47 |
| GH001 | GH Research | Phase 2 | 47 |
| Brexanolone | Brain Biotech | Pre-clinical | 15 |